Biomarker · Gene alteration
JAK2 V617F
JAK2 exon 14 point mutation p.V617F detected by allele-specific PCR or sequencing of blood; a diagnostic marker of myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, primary myelofibrosis).
CI-BIO-00000053JAK2graph →NCIt C105908
Also calledp.V617F · JAK2-positive · c.1849G>T
Derived
Associated cancers (4)
Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.
| Cancer | Items | Predictive | Prognostic | Diagnostic | Levels A / B / C / D / E |
|---|---|---|---|---|---|
| Chronic Myeloid Leukemia, BCR-ABL1 Positive | 2 | — | — | 2 | 0 / 2 / 0 / 0 / 0 |
| Polycythemia Vera | 2 | 2 | — | — | 0 / 1 / 0 / 1 / 0 |
| Lymphoid Leukemia | 1 | — | — | 1 | 0 / 1 / 0 / 0 / 0 |
| Malignant Bone Marrow Neoplasm | 1 | — | — | 1 | 0 / 1 / 0 / 0 / 0 |
Derived
Drugs with predictive evidence (2)
Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.
| Drug | CIViC items | Sensitivity | Resistance | Best level | Edges (S / R) | Cancer context |
|---|---|---|---|---|---|---|
| FedratinibSmall Molecule | 1 | 1 | — | D | 1 / 0 | Polycythemia Vera |
| Peginterferon Alfa-2bOther | 1 | 1 | — | B | 1 / 0 | Polycythemia Vera |
Curated evidence
Predictive evidence items (2)
ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 18394554
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| JAK2 V617F2 | ||||||||
| Fedratinib | ||||||||
Regulatory
Approvals mentioning the linked drugs (20)
Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.
- Source
- Health Canada — Drug Product Database (DPD)
- Dataset
- Health Canada DPD
- Version
- dpd-2026-09-11
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- Open Government Licence – Canada (https://open.canada.ca/en/open-government-licence-canada)
- Run
- ING-HEALTHCANADADPD-20260911-000001
Clinical trials
Active trials (2)
Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 2 recruiting · 0 active phase 3 · 5 in any status. Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 18, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04282187 | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | recruiting | Phase 2 | 25 |
Literature
Linked publications (4)
Publications linked to the scope variant(s) through PubMed entity edges; 25 per page, newest first.
- Source
- PubMed (NLM)
- Dataset
- PubMed E-utilities
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)